Toxic tau: structural origins of tau aggregation in Alzheimer’s disease

Abdullah Al Mamun1, Md. Sahab Uddin1,2,*, Bijlo Mathew3, Ghulam Md Ashraf4,5,*
1 Department of Pharmacy, Southeast University, Dhaka, Bangladesh
2 Pharmakon Neuroscience Research Network, Dhaka, Bangladesh
3 Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India
4 King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
5 Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

Abstract
Alzheimer’s disease is characterized by the extracellular accumulation of the amyloid β in the form of amyloid plaques and the intracellular deposition of the microtubule-associated protein tau in the form of neurofibrillary tangles. Most of the Alzheimer’s drugs targeting amyloid β have been failed in clinical trials. Particularly, tau pathology connects greatly in the pathogenesis of Alzheimer’s disease. Tau protein enhances the stabilization of microtubules that leads to the appropriate function of the neuron. Changes in the quantity or the conformation of tau protein could affect its function as a microtubules stabilizer and some of the processes wherein it is involved. The molecular mechanisms leading to the accumulation of tau are principally signified by numerous posttranslational modifications that change its conformation and structural state. Therefore, aberrant phosphorylation, as well as truncation of tau protein, has come into focus as significant mechanisms that make tau protein in a pathological entity. Furthermore, the shape-shifting nature of tau advocates to comprehend the progression of Alzheimer’s disease precisely. In this review, we emphasize the recent studies about the toxic and shape-shifting nature of tau in the pathogenesis of Alzheimer’s disease.

Key Words: Alzheimer’s disease; neurofibrillary tangles; shape-shifting nature of tau; tau aggregation; toxic tau

Introduction
Alzheimer’s disease (AD) is an irreversible progressive disorder that is featured by the most remarkable symptoms including memory loss and impairment of cognition (Kabir et al., 2019b; Uddin et al., 2019c). However, the specific process by which those symptoms progress remains abstruse. The foremost histopathological features of AD are the atypical aggregation of amyloid β (Aβ) and the tau protein (Kabir et al., 2019a; Uddin et al., 2019b). A number of researches recommend that in AD, the tiny oligomeric forms of both tau and Aβ may work synergistically to facilitate synaptic dysfunction. Most importantly, tau pathology plays a pivotal role in the development of AD than Aβ. In recent times, several studies have commenced advocating that the missorting of tau protein between the axon and the dendrites is a prerequisite to intervene with the harmful effects of Aβ (Guerrero-Muñoz et al., 2015; Uddin et al., 2019a).

The misfolding of protein is the preliminary phase in the accumulation process of both tau and Aβ (Uddin et al., 2020; Uddin and Kabir, 2019). There are two essential factors such as post-translational modifications and the formation of disulfide bridges raise the capability of both tau and Aβ proteins to self-assemble into oligomers (Sahara et al., 2007). It is evident that before the fibrils formation tau monomer is initially transformed into an oligomeric state. Moreover, accumulation of tau does not take place spontaneously but the fibril formation is induced by the combination of free fatty acids and polyanionic compounds (King et al., 2002). These different structures vary both in accumulation state and in their toxic actions. This review represents the precise point at which a healthy protein becomes toxic and shape-shifting nature of tau that aggregate and contribute to AD pathogenesis.

Toxic Tau and Alzheimer’s Pathogenesis
Experimental data recommend that tau in prefilamentous forms, precisely oligomers are considered as the neurotoxin. Before the commencement of the medical symptoms, oligomers of tau have been sequestered at very initial phases of the disease. Tau oligomers demonstrate a sphere-shaped morphology by using atomic force microscopy which links with two or more tau molecules, ranging from 6 to 20 nm (Sahara et al., 2008). In fact, these are dynamic structures that turn into β-sheet rich. The study of Himmelstein et al. (2012) exhibited that in AD brain samples, oligomers of tau were found at a 4-fold greater concentration than healthy control samples. Tau is aberrantly phosphorylated at various positions in AD as shown in Figure 1. Conversely, this may not only be a prerequisite for converting tau into oligomers as well as become toxic.

The detrimental accumulation trail inside a cell is assumed to initiate with a seed – a template that can prompt the aggregation of a specified protein. These seeds are believed to be vital in the disseminate of the disease. The study demonstrated that highly sulfated heparan sulfate (HS) aggregates with neurofibrillary tangles in the affected neurons of the...
AD brain (Snow et al., 1990). In the tau amyloidogenic process, the kinetic constants featuring the development of tau fibrils in the existence or deficiency of heparin agrees with a significant role of HS. Consequently, heparin can interact with two tau molecules yielding a dimer in vitro which is capable of forming fine tiny fibrils (Ramachandran and Udgaonkar, 2011). Conversely, a plethora of heparin can linger the accumulation of tau lag phase, recommending a regulatory role throughout the nucleation phase (Zhu et al., 2010).

**Spreading and Propagating of Tau in Alzheimer’s Disease**

Some steps such as cellular uptake, templated seeding, secretion and intercellular transfer through synaptic and non-synaptic pathways are anticipated to incorporate for the proliferation of tau pathology by using prion-like mechanisms (Mudher et al., 2017). It is unclear that accumulated tau can be absorbed by cells via precise mechanisms. Ingestion of tau accumulation is done by macropinocytosis (Holmes et al., 2013; Falcon et al., 2015) as well as needs HS proteoglycans (Holmes et al., 2013). After ingestion, tau seeds present in endosomes and must allow contacting with the cytosol to trigger the accumulation of non-accumulated tau.

Two experiments have claimed that in a transgenic mouse line, obvious trans-synaptic movement of tau protein accumulates depend on area-specific gene expression. Tetracycline-controlled gene expression was conducted principally in the entorhinal cortex in both studies that project axons to the hippocampus. In addition, aggregate pathology that was most probably to have derived from the entorhinal neurons was found in the hippocampus in older animals (de Calignon et al., 2012; Liu et al., 2012). The study of Dujardin et al. (2014) using a lentivirus-directed rat model of hippocampal tauopathy showed that wild-type tau is shifted through axons to faraway second-order neurons. Moreover, these investigations powerfully recommended that accumulated tau were passing across synapses, and therefore could possibly elucidate the connection of neural systems in neurodegenerative diseases. Ultimately, current study offerings irrefutable indication that tau proliferates steadily distinctive accumulate conformations, or strains, in cells and mice, as well as that human tauopathies are comprised of disease-related strains (Sanders et al., 2014).

HS can take part both in the tau accumulation processes and its aberrant phosphorylation in the AD brain that may precede or concurrently takes place with its accumulation (Maïza et al., 2018). Apart from this prospective role that HS appears to play in the tau phosphorylation processes as well as accumulation, these polysaccharides have also played an essential role in the proliferation of tau proteopathic particles/seeds between one cell and another cell, an event called as spreading (Holmes et al., 2013). Undeniably, tauopathy is identified in specific brain areas in early AD whereas, as the disease develops, tauopathy seems in other areas (Goedert and Spillantini, 2017).

**Deadly Shape-Shifting Nature of Tau in Alzheimer’s Pathology**

The postulate is that seeds can alter the typically folded protein into an accumulation of the identical protein, prior to cells release them into the surroundings for adjoining cells to start (Eisenberg and Jucker, 2012). Furthermore, this could be exactly how diseases associated with the tau protein, for instance, AD proliferate from one cell to another. Then, there, the accumulation would travel via the brain using the links from neurons to neurons (Sanders et al., 2014). Although, most of the researchers have thought that they are an aggregate of a given distinct misfolded protein, the identity of the seeds remains vague, hitherto. Mirbaha et al. (2018) recommended that the presence of a stable form of a distinct tau protein that can initiate the accumulation process on its individual. It is evident that the seed may not only be an aggregate of a misfolded protein but instead be a protein monomer – with a
Conclusion

It is well-known that the hyperphosphorylated tau is closely connected with neurodegeneration as well as cognitive dysfunction in AD. It has been admitted that aberrant forms of tau protein are directly associated with the commencement of neurodegenerative processes of AD. The current study recognized the concept of shape-shifting which might connect with other proteins that generate toxic accumulates. Therefore, this can support to comprehend clearly the development and progression of neurodegenerative events. Remarkably, the structures that tau forms could be classified as either ‘good’ or ‘bad’ might also aid to advance novel therapies for AD. Medicine can be formulated whether to eradicate the bad form of tau from the brain or to stabilize the good form of tau. Furthermore, if the shape-shift could be diagnosed initially in patients, it might permit therapies for AD prior to patients have developed any evident symptoms.

Acknowledgments: The authors concede the support by the Pharmakon Neuroscience Research Network, Dhaka, Bangladesh.

Author contributions: This work was carried out in collaboration between all authors. All authors read and approved the final submitted version of the manuscript.

Conflicts of interest: The authors proclaim no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Chirita CN, Congdon EE, Yin H, Kuret J (2005) Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry 44:5862–5872.

de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73:685–697.

Dujardin S, Lécotile K, Caillérez R, Bégaud S, Zimmer N, Lachaud C, Carrier S, Dufour N, Aurégné G, Winderickx J, Hantraye P, Déglon N, Colin M1, Buée L (2014) Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun 2:14.

Eisenberg D, Jucker M (2012) The amyloid state of proteins in human diseases. Cell 148:1188–1203.
Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, Jackson S, O’Neill MJ, Isaacs AM, Hutton ML, Szekeres PG, Goedert M, Bose S (2015) Conformation determines the seeding potencies of native and recombinant Tau aggregates. J Biol Chem 290:1049-1065. Goedert M, Spillantini MG (2017) Propagation of Tau aggregates. Mol Brain 10:18.

Guerrero-Muñoz MJ, Gerson J, Castillo-Carranza DL (2015) Tau oligomers: The toxic player at synapses in Alzheimer's disease. Front Cell Neurosci 9:1-10.

Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378-384.

Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI (2012) Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 136:8-22.

Holmes BB, DeVos SL, Flourney N, Li M, Jacks R, Yanamandra K, Ouidja Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI (2012) The trans-cholinesterase inhibitors for Alzheimer's disease: multitargeting strategy based on anti-Alzheimer's drugs repositioning. Curr Pharm Des 25:1-17.

Kabir MT, Abu Sufian M, Uddin MS, Begum MM, Akhter S, Islam A, Mathew B, Islam MS, Amran MS, Md Ashraf G (2019a) Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease. Sci Total Environ 700:134836.

Uddin MS, Kabir MT (2019) Emerging signal regulating potential of genistein against Alzheimer's disease: a promising molecule of interest. Front Cell Dev Biol 7:197.

Uddin MS, Kabir MT, Tewari D, Mathew B, Aleya L (2020) Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease. Sci Total Environ 700:134836.

Uddin MS, Kabir MT, Tewari D, Mathew B, Aleya L (2020) Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease. Sci Total Environ 700:134836.